Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

TherOx pushes for FDA approval with $30m:

This article was originally published in Clinica

Executive Summary

TherOx, an Irvine, California-based company that is developing an oxygen therapy to help heart attack patients, has secured $30m to help take its product through to FDA approval. The financing was led by DAG Ventures. Some of the funds will also be used to initiate US commercialisation of the device, pending approval. TherOx's SuperSaturated Oxygen (SSO2) therapy is designed as an adjunct to balloon angioplasty and stent procedures. It helps to salvage heart muscle by delivery highly oxygenated arterial blood directly to tissue damaged by myocardial infarction.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT046410

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel